ISAR Lectures on DocMode

1. Dr. Shreyas and Mr. PP Gadgil :

Topic : New Reality - Virtual Accreditation of IVF lab...Is it possible?
Date : 30.04.2020
Link : Click here for » View Link

2. Dr.Rajul Tyagi :

Topic : Tips and Trick of Ovulation Trigger
Date : 23.04.2020
Link : Click here for » View Link

3. Dr. Jayesh Amin :

Topic : Right approach to Ovulation Induction in ART
Date : 16.04.2020
Link : Click here for » View Link

Dr. Jatin Shah - MD, DGO Gold medalList (Mumbai university) - Specialist in Assisted Reproduction

Topic : Management of poor responders
Date : 9.04.2020
Time : 3-4 pm
Link : Click here for » View Link

Poor responders constitute almost 30-40% of IVF patients in urban practice and are an extremely challenging group of patients to treat. For Poseidon groups 1 and 2 (Young and old patients with normal ovarian reserve) judicious pretreatment with estradiol, norethisterone, the GnRH antagonist or short duration of OCP is mandatory to ensure a uniform cohort of follicles and optimise the number of mature oocytes retrieved. In some patients, increasing the FSH dose in subsequent cycles (never > 300 IU) or addition of LH might be beneficial. Some of these patients (especially hypo responders) might be carriers for polymorphisms of the FSH and LH receptors and it might be useful to have these tested before beginning ovarian stimulation. Also, in the author's experience, the use of the long agonist protocol with HP-HMG gives a higher yield of top quality embryos and better pregnancy rates than the conventional short antagonist protocol. For groups 3 and 4 (Young and old patients with a diminished ovarian reserve) stepping up FSH doses beyond 150 IU is futile and again the agonist with HMG might be better than the antagonist. The use of the dual trigger (hCG with agonist) is recommended for a higher yield of metaphase II oocytes in poor responders. The emphasis should be on getting the maximal yield of mature oocytes as there is an increase in live birth rates with every extra oocyte retrieved. Dual stimulation might be useful for some of these patients as the luteal phase stimulation has been shown to yield a higher proportion of euploid blastocysts in two studies but further RCTs are awaited. Ovarian activation with PRP seems promising but more data is required. ICSI does not offer any benefit over conventional IVF for poor responders and should be avoided. Adjuvants in the form of coenzyme Q and testosterone might be useful but further RCTs are awaited. Growth hormone, DHEA, aspirin and other adjuvants have not been found to be useful for poor responders. Finally, oocyte donation remains a viable option for poor responders who fail repeated IVF cycles.

5. Dr. Prakash Trivedi :

Topic : Current Understanding of the Management of Fibroids in Infertility & ART
Date : 02.04.2020
Link : Click here for » View Link

6. Dr.Ameet Patki :

Topic : Have we reached the crossroads in Management of PCOS?
Date : 26.03.2020
Link : Click here for » View Link

7. Dr. Narendra Malhotra :

Topic : Ultrasound and Hysteroscopy - The two Magic Sticks in Management of Infertility
Date : 12.03.2020
Link : Click here for » View Link

8. Dr. Madhuri Patil :

Topic : Evidence for Surgery in Infertility
Date : 27.02.2020
Link : Click here for » View Link

9. Dr. Jaideep Malhotra :

Topic : Right Choice Right Time - Case Selection for Infertility Management
Date : 13.02.2020
Link : Click here for » View Link